Results at week 264
FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Consistent range of response through 5 years, mNRI and observed30
In an mNRI analysis of patients receiving Taltz at week 60, 93% of patients achieved PASI 75, 83% of patients achieved PASI 90, and 56% of patients achieved PASI 100. In an mNRI analysis of patients receiving Taltz at weeks 108, 156, 204, and 264, 89%, 83%, 86%, and 91% of patients, respectively, achieved PASI 75; 80%, 68%, 71%, and 69% of patients, respectively, achieved PASI 90; and 54%, 48%, 45%, and 44% of patients, respectively, achieved PASI 100.
SELECT IMPORTANT SAFETY INFORMATION
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis, and conjunctivitis, influenza, and urticaria in pediatric psoriasis.